Johannes Jacob Pieter Kastelein - 02 Jan 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Scientific Officer, Director
Signature
/s/ Louise Kooij by Power of Attorney from Johannes Jacob Pieter Kastelein
Issuer symbol
NAMS
Transactions as of
02 Jan 2025
Transactions value $
$0
Form type
4
Filing time
06 Jan 2025, 17:48:27 UTC
Previous filing
27 Mar 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Award $0 +200K $0.00 200K 02 Jan 2025 Ordinary Shares 200K $25.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.